Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 4
1952 2
1953 1
1955 2
1956 1
1984 1
1988 1
1991 2
1994 2
1996 2
2000 2
2001 2
2003 4
2004 6
2005 2
2006 1
2009 2
2010 3
2012 3
2013 1
2014 4
2015 4
2016 3
2017 2
2018 7
2019 3
2020 9
2021 14
2022 7
2023 4
2024 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmaña J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Jóhannsson ÓÞ, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marmé F, Martinez de Dueñas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Španić T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ; OlympiA Clinical Trial Steering Committee and Investigators. Geyer CE Jr, et al. Ann Oncol. 2022 Dec;33(12):1250-1268. doi: 10.1016/j.annonc.2022.09.159. Epub 2022 Oct 10. Ann Oncol. 2022. PMID: 36228963 Free PMC article. Clinical Trial.
Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, Sciortino T, Mau CY, Bruno F, Nunez L, Morshed RA, Haddad AF, Weller M, van den Bent M, Beck J, Hervey-Jumper S, Molinaro AM, Tandon N, Rudà R, Vogelbaum MA, Bello L, Schnell O, Grau SJ, Chang SM, Berger MS, Esquenazi Y, Tonn JC. Karschnia P, et al. Among authors: mau cy. Neuro Oncol. 2023 Sep 5;25(9):1672-1685. doi: 10.1093/neuonc/noad074. Neuro Oncol. 2023. PMID: 37253096 Free PMC article.
Neuroleukemiosis: Diagnosis and management.
Mau C, Ghali MGZ, Styler M, Malysz J, Specht CS, Rizk E. Mau C, et al. Clin Neurol Neurosurg. 2019 Sep;184:105340. doi: 10.1016/j.clineuro.2019.04.019. Epub 2019 Apr 17. Clin Neurol Neurosurg. 2019. PMID: 31387077 Review.
Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists.
Rotstein DM, Melville CR, Padilla F, Cournoyer D, Lee EK, Lemoine R, Petersen AC, Setti LQ, Wanner J, Chen L, Filonova L, Loughhead DG, Manka J, Lin XF, Gleason S, Sankuratri S, Ji C, Derosier A, Dioszegi M, Heilek G, Jekle A, Berry P, Mau CI, Weller P. Rotstein DM, et al. Among authors: mau ci. Bioorg Med Chem Lett. 2010 May 15;20(10):3116-9. doi: 10.1016/j.bmcl.2010.03.095. Epub 2010 Mar 30. Bioorg Med Chem Lett. 2010. PMID: 20417098
Prophylactic Surgery: For Whom, When and How?
Mau C, Untch M. Mau C, et al. Breast Care (Basel). 2017 Dec;12(6):379-384. doi: 10.1159/000485830. Epub 2017 Dec 13. Breast Care (Basel). 2017. PMID: 29456469 Free PMC article. Review.
Extracranial medulloepithelioma: a review of the literature.
Bailey D, Mau C, Toepke C, Finch E, Rizk E. Bailey D, et al. Among authors: mau c. Childs Nerv Syst. 2022 Jul;38(7):1259-1266. doi: 10.1007/s00381-022-05525-4. Epub 2022 Apr 27. Childs Nerv Syst. 2022. PMID: 35474542 Review.
Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group.
Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, Sciortino T, Mau CY, Bruno F, Nunez L, Morshed RA, Haddad AF, Weller M, van den Bent M, Thon N, Beck J, Hervey-Jumper S, Molinaro AM, Tandon N, Rudà R, Vogelbaum MA, Bello L, Schnell O, Grau SJ, Chang SM, Berger MS, Esquenazi Y, Tonn JC. Karschnia P, et al. Among authors: mau cy. Neuro Oncol. 2024 Mar 4;26(3):584-586. doi: 10.1093/neuonc/noad237. Neuro Oncol. 2024. PMID: 38164632 Free PMC article. No abstract available.
How enhancers regulate wavelike gene expression patterns.
Mau C, Rudolf H, Strobl F, Schmid B, Regensburger T, Palmisano R, Stelzer EHK, Taher L, El-Sherif E. Mau C, et al. Elife. 2023 Jul 11;12:e84969. doi: 10.7554/eLife.84969. Elife. 2023. PMID: 37432987 Free PMC article.
94 results